Two year survival rates of 55% to 63% in pretreated dMMR mCRC with pembrolizumab -we know it is effective yet still do not have access for our patients in Canada...unacceptable! Phase II KEYNOTE-164 #CRCsm
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164